Search

Your search keyword '"Bijl, Tom"' showing total 25 results

Search Constraints

Start Over You searched for: Author "Bijl, Tom" Remove constraint Author: "Bijl, Tom"
25 results on '"Bijl, Tom"'

Search Results

2. Broad SARS-CoV-2 neutralization by monoclonal and bispecific antibodies derived from a Gamma-infected individual

3. Germline-targeting HIV-1 Env vaccination induces VRC01-class antibodies with rare insertions

4. Identification of IOMA-class neutralizing antibodies targeting the CD4-binding site on the HIV-1 envelope glycoprotein

5. A public antibody class recognizes an S2 epitope exposed on open conformations of SARS-CoV-2 spike

6. Lassa virus glycoprotein nanoparticles elicit neutralizing antibody responses and protection

7. COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models

8. Immunofocusing and enhancing autologous Tier-2 HIV-1 neutralization by displaying Env trimers on two-component protein nanoparticles

9. Identification of New Drugs to Counteract Anti-Spike IgG-Induced Hyperinflammation in Severe COVID-19

10. Enhancing and shaping the immunogenicity of native-like HIV-1 envelope trimers with a two-component protein nanoparticle

11. Complementary antibody lineages achieve neutralization breadth in an HIV-1 infected elite neutralizer

12. Broad SARS-CoV-2 Neutralization by Monoclonal and Bispecific Antibodies Derived from a Gamma-infected Individual

13. Lassa virus glycoprotein nanoparticles elicit a neutralizing antibody that defines a new site of vulnerability

14. HIV-1 Germline-Targeting Vaccine Regimen Selects for Rare Immunoglobulin Insertions and Deletions Typical of VRC01-Class Antibodies

16. A public antibody class recognizes a novel S2 epitope exposed on open conformations of SARS-CoV-2 spike

17. Cross-reactive antibodies after SARS-CoV-2 infection and vaccination

18. COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models

19. Immunofocusing and enhancing autologous Tier-2 HIV-1 neutralization by displaying Env trimers on two-component protein nanoparticles

20. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability

21. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability

22. Cross-reactive antibodies after SARS-CoV-2 infection and vaccination.

23. The molecular immune modulator adenosine deaminase-1 enhances HIV specific humoral and cellular responses to a native-like HIV envelope trimer DNA vaccine.

24. Identification of new drugs to counteract anti-spike IgG-induced hyperinflammation in severe COVID-19.

25. Broad SARS-CoV-2 Neutralization by Monoclonal and Bispecific Antibodies Derived from a Gamma-infected Individual.

Catalog

Books, media, physical & digital resources